Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Operating Expenses (2019 - 2026)

InMed Pharmaceuticals has reported Other Operating Expenses over the past 5 years, most recently at $35065.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 60.49% year-over-year to $35065.0; the TTM value through Dec 2025 reached $225938.0, down 6.1%, while the annual FY2025 figure was $191106.0, 24.69% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $35065.0 at InMed Pharmaceuticals, down from $110196.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $145839.0 in Q3 2022 and troughed at -$8.8 million in Q2 2022.
  • A 5-year average of -$868019.1 and a median of $31798.5 in 2021 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 448.39% in 2024 and fell as far as 75.76% in 2024.
  • Year by year, Other Operating Expenses stood at -$4.2 million in 2021, then soared by 99.45% to -$23286.0 in 2022, then decreased by 24.71% to -$29040.0 in 2023, then skyrocketed by 405.6% to $88746.0 in 2024, then tumbled by 60.49% to $35065.0 in 2025.
  • Business Quant data shows Other Operating Expenses for INM at $35065.0 in Q4 2025, $110196.0 in Q3 2025, and $18409.0 in Q2 2025.